Roche is leaving PhRMA for BIO. Genentech, which Roche recently acquired, was a member of BIO and during the reorganization of the companies, Roche assets in the US became Genentech. "Genentech and Roche believe BIO's purpose is closely aligned with the direction of the new company and, therefore, can represent the company's interest in Washington,'' Roche's Darian Wilson said in a statement.